Final Program

40 SUNDAY • MAY 15
103 Immunosuppressant Response Among Individuals Meeting
Criteria for Interstitial Pneumonia with Autoimmune
Features/J.M. Oldham, A. Adegunsoye, L.J. Witt, E. Valenzi, C.T.
Lee, L.W. Chen, S. Hsu, J. Chung, S. Montner, I. Noth, R. Vij, M.E.
Strek, Chicago, IL, p.A1136
104 Quantitative CT as an Outcome Measure in the Scleroderma
Lung Study II/J.G. Goldin, E. Kleerup, P. Lu, P. Clements, M.
Brown, M.D. Roth, D.P. Tashkin, Los Angeles, CA, p.A1133
105 Factors Associated with Relapse of Cryptogenic and
Secondary Organizing Pneumonia/Y. Onishi, T. Kawamura, R.
Kagami, 8520, Japan, p.A1134
106 Radiological Versus Histological Diagnosis in Antisynthetase
-Associated Interstitial Lung Disease/J.A. Huapaya, L.L. Silhan,
S.K. Danoff, Baltimore, MD, p.A1135
107 Additional Clinical Signs and Symptoms Develop in Patients
with Antisynthetase Syndrome-Associated Interstitial Lung
Disease Followed Over 24 Months/J.A. Huapaya, L.L. Silhan,
S.K. Danoff, Baltimore, MD, p.A1150
108 Clinico-Radiological-Pathological Characteristics of Idiopathic
Pleuroparenchymal Fibroelastosis/K. Gocho, K. Sugino, K.
Furuya, Y. Nakamura, T. Isshiki, T. Uekusa, K. Shibuya, S.
Homma, Tokyo, Japan, p.A1137
109 Transitional Voxel-Wise Changes in the Interstitial Lung
Disease on High Resolution Computed Tomography using
Scleroderma Lung Study-II/G.H. Kim, D. Tashkin, P. Lo, P. Lu, M.
Brown, E. Kleerup, M.D. Roth, J. Goldin, Los Angeles, CA, p.A1138
110 Clinical Information of Secondary Pulmonary Alveolar
Proteinosis in Japan: A Follow-Up Report
(KAKEN26305028/AMED:H27-063)/H. Ishii, R. Tazawa, T. Saraya,
Y. Inoue, K. Nakata, Mitaka, Japan, p.A1139
111 Short-Term Efficacy of Treatment in Myositis-Associated
ILD/M. Hachem, H. Nunes, J. Obert, Y. Uzunhan, D. Valeyre, J.
Cadranel, J.-M. Naccache, Paris, France, p.A1140
112 Observational Study of Therapeutic Response to
Immunosuppression of CTD-ILD Versus AIF-ILD/R. Parikh, P.
Chung, K. Kuchta, R. Vij, S. Bellam, Evanston, IL, p.A1141
113 Pleuroparenchymal Fibroelastosis (PPFE) Predicts Survival in
Idiopathic Pulmonary Fibrosis (IPF)/A. De Lauretis, H. Basra, W.
Hakim, J. Jacob, D. Visca, M. Kokosi, M. Bonifazi, E. Renzoni,
D.M. Hansell, A.U. Wells, London, United Kingdom, p.A1142
114 Lung Cancer in Connective Tissue Disease-Associated
Interstitial Lung Disease: Clinical Features and Impact on
Outcome/S. Watanabe, Y. Waseda, H. Takato, R. Matsunuma, K.
Saeki, J. Hara, T. Sone, M. Abo, H. Kimura, K. Kasahara,
Kanazawa, Japan, p.A1143
115 Rheumatoid Arthritis Associated Usual Interstitial Pneumonia:
Correlation of Histologic Features with Prognosis/Y. Tsuchiya,
D.A. Lynch, T. Johkoh, J. Fukuoka, T. Colby, S. Groshong, H.
Taniguchi, K. Ichikado, A. Shiraki, N. Tanaka, H. Arakawa, Y.
Waseda, K.K. Brown, J.J. Swigris, J.J. Solomon, Tokyo, Japan,
p.A1144
116 Whole Lung Lavage Therapy of Pulmonary Alveolar
Proteinosis: A Global Survey of Current Practices and
Procedures/I. Campo, M. Luisetti, M. Griese, B.C. Trapnell, F.
Bonella, J.C. Grutters, K. Nakata, C.H.M. Van Moorsel, U.
Costabel, V. Cottin, T. Ichiwata, Y. Inoue, A. Braschi, G. Bonizzoni,
G.A. Iotti, C. Tinelli, G. Rodi, Pavia, Italy, p.A1145
117 Serum Anti-ARS and Anti-MDA-5 Antibodies Are Useful
Biomarkers for Predicting the Prognosis in Patients with
Polymyositis/Dermatomyositis-Associated Interstitial Lung
Disease/H. Hozumi, T. Fujisawa, M. Kono, N. Enomoto, N. Inui, Y.
Nakamura, T. Suda, Hamamatsu, Japan, p.A1146
118 Rituximab in Progressive, Refractory to Conventional
Treatment, Interstitial Lung Disease/M.A. Kokosi, G. Keir, T.
Corte, L. Troy, P. Saunders, F. Chua, T.M. Maher, E. Renzoni, A.U.
Wells, London, United Kingdom, p.A1147
119 Comparison of CTD-ILD, Autoimmune Featured ILD, and ILD
with a Positive Autoimmune Serologic Marker/P. Chung, R.
Parikh, K. Kuchta, R. Vij, S. Bellam, Evanston, IL, p.A1148
120 Acute Fibrinous and Organizing Pneumonia: A Newly
Recognized, but Poorly Understood Disease/A. Moraco, E.
Bozkurtlar, U. Hironori, A. Akalin, E. Mark, S. Kopec, Worcester,
MA, p.A1149
121 Prevalence of Unclassifiable Interstitial Lung Disease (ILD) in a
University Hospital in Buenos Aires, Argentina/M.A. Grosso, P.
Rossi, G. Legarreta, S. Acuna, J.I. Enghelmayer, Buenos Aires,
Argentina, p.A1151
122 Radiographic and Physiologic Abnormalities in Subjects with
Myositis-Associated Interstitial Lung Disease/D. Assayag, A.
Hirsch, M. Baron, M. Hudson, Montreal, Canada, p.A1152
123 Lung Cancer in Patients with Interstitial Lung Disease:
Idiopathic Versus Connective Tissue Disease-Related
Subtypes/K. Saeki, S. Watanabe, Y. Waseda, H. Takato, R.
Matsunuma, J. Hara, T. Sone, M. Abo, H. Kimura, K. Kasahara,
Kanazawa, Japan, p.A1153
124 Idiopathic Pleuroparenchymal Fibroelastosis and Its
Mimickers/S. Tomassetti, D.M. Nicotra, J.H. Ryu, S. Piciucchi, A.
Dubini, P. Tantalocco, C. Ravaglia, C. Gurioli, A. Rossi, M. Chilosi,
G.U. Di Maria, V. Poletti, Forli, Italy, p.A1154
125 Effect of Mycophenolate Mofetil on Scleroderma-associated
Interstitial Lung Disease/M. Baqir, A. Makol, T.G. Osborn, B.
Bartholmai, J. Ryu, Rochester, MN, p.A1155
A25
POSTER DISCUSSION SESSION
CRITICAL CARE: FUNCTIONAL OUTCOMES IN ICU
SURVIVORS
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3001 (West Building, Level 3)
Poster Viewing 9:00-9:45
Discussion 9:45-11:00
ATS 2016 • San Francisco